CORAL GABLES, Fla., Oct. 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023, being held November 10-14, 2023, in Boston, MA.
Read more at prnewswire.comRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here